Physician profile
Alberto Casaretto
NPI 1821190703
$7,931.53
in general payments reported to CMS, 2019-2025
29 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $779 · 2021: $886 · 2022: $1,566 · 2023: $560 · 2024: $1,298 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943 · Education: $35.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.38 |
| Education | $35.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,436.51 | 2019-2025 | Lokelma, Farxiga, Flumist Quadrivalent |
| Travere Therapeutics, INC. | $1,075.59 | 2019-2025 | |
| Amgen INC. | $711.78 | 2019-2024 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $508.44 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $476.66 | 2019-2024 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $467.17 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $374.78 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $358.58 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $338.04 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $274.62 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $264.76 | 2022-2025 | Tarpeyo |
| Baxter Healthcare | $231.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $207.89 | 2020-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $193.02 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $182.48 | 2019-2024 | Ultomiris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $168.69 | 2021-2024 | Lupkynis |
| Boston Scientific Corporation | $130.52 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $123.37 | 2019 | |
| Fresenius USA Marketing, INC. | $98.74 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.76 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $39.39 | 2022-2024 | Purified Cortrophin Gel |
| Amicus Therapeutics, INC. | $38.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.15 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.44 | 2023 | Oxlumo |
| Novo Nordisk INC | $23.56 | 2025 | Ozempic |
| Apellis Pharmaceuticals, INC. | $21.95 | 2025 | Empaveli |
| Shire North American Group INC | $20.49 | 2019 | |
| Genzyme Corporation | $19.46 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Casaretto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.